Skip to main content
letter
. 2022 Feb;17(2):283–285. doi: 10.2215/CJN.10000721

Figure 1.

Figure 1.

Changes in the number of patients with new CKD stages 3 to 4 per VA location identified using the 2021 CKD-EPI creatinine eGFR equation. The total change in the number of patients with CKD stages 3 to 4 using the 2021 CKD-EPI creatinine eGFR equation compared with the 2009 CKD-EPI equation varied across VA locations (A). Each bar represents an individual VA location. The increase in CKD stages 3 to 4 among Black persons (shown in orange) and persons of unidentified race whose eGFR was not calculable using a race-based equation (shown in dark blue), and the decrease in CKD stages 3 to 4 among non-Black persons (shown in gray) are shown for the ten VA locations with the greatest total decrease (B) and the greatest total increase (C) in patients with CKD stages 3 to 4.